|1.||Cai, Yunqing: 4 articles (01/2015 - 06/2010)|
|2.||Lu, Qiu Jun: 3 articles (11/2011 - 06/2010)|
|3.||Zou, Li Bo: 3 articles (11/2011 - 06/2010)|
|4.||Fu, Jie Ying: 3 articles (11/2011 - 06/2010)|
|5.||Liu, Rui Ting: 3 articles (11/2011 - 06/2010)|
|6.||Kang, Hee E: 3 articles (01/2011 - 01/2010)|
|7.||Lee, Myung G: 3 articles (01/2011 - 01/2010)|
|8.||Lee, Jee W: 3 articles (01/2011 - 01/2010)|
|9.||Kim, Dong-Hyun: 2 articles (05/2015 - 03/2007)|
|10.||Zhou, Ming: 2 articles (01/2015 - 06/2010)|
|1.||Liver Diseases (Liver Disease)
01/01/2015 - "The results demonstrated that liquiritigenin is effective in protecting liver from injury or treating chronic liver diseases. "
10/01/2010 - "Liquiritigenin (LQ) is a candidate for the treatment of inflammatory liver disease. "
06/01/2009 - "Pharmacokinetics of liquiritigenin, a candidate for inflammatory liver disease, and its two glucuronide conjugates, M1 and M2, were evaluated in rats. "
01/01/2015 - "Here, we investigated the efficacy and mechanism of liquiritigenin involved in preventing or retarding the progression of liver diseases in a rat model with chronic carbon tetrachloride (CCl4) exposure. "
01/01/2011 - "The pharmacokinetics of liquiritigenin (LQ), a candidate therapy for inflammatory liver disease, and its metabolites M1 and M2 were evaluated in rats with ARF induced by uranyl nitrate (U-ARF rats). "
01/10/2005 - "When the antitussive effects of liquiritin apioside, liquiritin and liquiritigenin, at respective doses of 30 mg/kg, p.o., were examined 1 h after administration, liquiritin apioside and liquiritigenin caused a significant reduction in the number of capsaicin-induced coughs. "
01/10/2005 - "On the other hand, when the antitussive effects of liquiritin apioside, liquiritin and liquiritigenin, at doses of 30 mg/kg, p.o., were examined 4 h after administration, each caused a more than 40% reduction in the number of capsaicin-induced coughs. "
01/01/2012 - "In our studies, liquiritigenin effectively inhibited the growth of tumors xenografted in nude mice from human cervical cancer cell line HeLa cells, and microvascular density (MVD) of the tumor exposed to liquiritigenin was reduced in a dose dependent manner, especially in the high dose group. "
05/01/2012 - "Immunohistochemical analysis of tumors revealed a significant increase in the nuclear ERβ expression with a concomitant decrease in cell proliferation in the liquiritigenin-treated group. "
05/01/2012 - "Compared with control mice, animals treated with liquiritigenin had greater than 50% reduction in tumor volume and size. "
01/01/2012 - "Liquiritigenin inhibits tumor growth and vascularization in a mouse model of HeLa cells."
06/01/2010 - "After mice were administrated liquiritigenin (10, 20 and 40 mg/kg) intragastrically for 15 days, tumor volume, indices of thymus and spleen, MDA level in serum, optical microscopy, electron microscopy were determined. "
|4.||Breast Neoplasms (Breast Cancer)
02/01/2013 - "In this study we tested to what extent two ERβ agonists, androgen derivative 3β-Adiol and flavonoid Liquiritigenin, would affect growth and gene expression of different ERβ-positive human breast cancer cell lines. "
02/13/2008 - "In a mouse xenograph model, liquiritigenin did not stimulate uterine size or tumorigenesis of MCF-7 breast cancer cells. "
11/01/2013 - "We examined the interactions of genistein, daidzein, equol, and liquiritigenin with estrogen receptors ERα and ERβ, with key coregulators (SRC3 and RIP140) and chromatin binding sites, and the regulation of gene expression and proliferation in MCF-7 breast cancer cells containing ERα and/or ERβ. "
|5.||Alzheimer Disease (Alzheimer's Disease)
07/01/2009 - "Therefore, liquiritigenin may be useful for further study as a prodrug for treatment of Alzheimer's disease.Acta"
11/01/2011 - "These findings provide evidence for beneficial activity of liquiritigenin in a mouse model of Alzheimer's disease and support the continued investigation of Notch signaling pathway as a target for treatment of Alzheimer's disease."
06/26/2010 - "These findings provide evidence for the beneficial activity of liquiritigenin in a brain-injured rat model and support the continued investigation of SERMs such as liquiritigenin as an alternative to estrogen-based hormone therapy in reducing the risk of neurodegenerative diseases such as Alzheimer's disease."
|6.||JNK Mitogen-Activated Protein Kinases
|7.||Estrogen Receptor beta
|9.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Complementary Therapies (Alternative Medicine)